Copanlisib as a Treatment for Patients With Relapsed/Refractory Indolent B-Cell Lymphoma

Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.